Raab & Moskowitz Asset Management LLC boosted its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 3.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,756 shares of the biopharmaceutical company’s stock after acquiring an additional 1,841 shares during the quarter. Bristol-Myers Squibb accounts for approximately 1.5% of Raab & Moskowitz Asset Management LLC’s investment portfolio, making the stock its 19th biggest holding. Raab & Moskowitz Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $2,985,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Blue Chip Partners Inc. lifted its position in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 15 shares in the last quarter. Shayne & CO. LLC lifted its position in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 24 shares in the last quarter. Chilton Investment Co. LLC lifted its position in Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 26 shares in the last quarter. Finally, Greenleaf Trust lifted its position in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 39 shares in the last quarter. 69.82% of the stock is currently owned by institutional investors and hedge funds.

In related news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.23% of the company’s stock.

BMY has been the topic of several recent research reports. Jefferies Group reaffirmed a “buy” rating and issued a $66.00 price target (up previously from $63.00) on shares of Bristol-Myers Squibb in a research report on Thursday, August 24th. Vetr cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 target price on the stock. in a research report on Tuesday, August 22nd. Goldman Sachs Group reissued a “buy” rating and set a $65.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. UBS reissued a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $64.93.

Shares of Bristol-Myers Squibb Company (BMY) opened at $63.28 on Wednesday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market cap of $103,144.84, a P/E ratio of 21.29, a P/E/G ratio of 2.39 and a beta of 1.18. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the firm posted $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date of this dividend is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is 61.42%.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/raab-moskowitz-asset-management-llc-raises-stake-in-bristol-myers-squibb-company-bmy/1761301.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with Analyst Ratings Network's FREE daily email newsletter.